JERUSALEM--(BUSINESS WIRE)--Jul. 2, 2013--
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development
company, announced today that its Chief Executive Officer, Kinneret
Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip
Serlin, will be presenting at the 2013 Annual JMP Securities Healthcare
Conference at the St. Regis Hotel in New York.
The BioLineRx presentation is currently scheduled to start at 4:30 p.m.
EDT on Tuesday, July 9th. The presentation will be broadcast
over the Internet as a "live" listen only Webcast. To listen, please go
An archive of the event will also be available for those unable to
In addition, investors attending the conference who wish to meet with
Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact
their JMP Securities representative.
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of seven clinical stage
candidates: BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, which has been out-licensed to Ikaria
Inc., is currently undergoing a pivotal CE-Mark registration trial;
BL-5010 for non-surgical removal of skin lesions has completed a Phase
1/2 study; BL-7040 for treating inflammatory bowel disease (IBD) has
completed a Phase 2a trial; BL-8040 for treating acute myeloid leukemia
(AML) and other hematological cancers has commenced a Phase 2 study;
BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; BL-1021
for neuropathic pain is in Phase 1 development; and BL-1020 for
schizophrenia. In addition, BioLineRx has five products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s Office of the Chief Scientist (OCS). The final stage
includes partnering with medium and large pharmaceutical companies for
advanced clinical development (Phase 3) and commercialization. For more
information on BioLineRx, please visit www.biolinerx.com,
the content of which does not form a part of this press release.
KCSA Strategic Communications
Garth Russell / Todd Fromer
212-896-1250 / +1 212-896-1250